Phrma Lobbying Interests

682 Words2 Pages

The pharmaceutical industry has a high stake in the passage of laws and they protect their interests by maintaining a substantial presence of lobbyists. In 2010, there were approximately 3,000 health care lobbyists in Washington (Attkisson). Pharmaceutical Research and Manufacturers of America (PhRMA) is a trade group that represents 48 pharmaceutical companies and is one of the largest lobbying groups in Washington. They currently represent some of the largest pharmaceutical companies including Bayer HealthCare LLC, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., and Pfizer (PhRMA). PhRMA works to secure the interests of its clients through their lobbying efforts. In addition to their work under the PhRMA name, they also have …show more content…

PhRMA accomplishes these goals through the advocacy of public policies, research, and effective regulation of the industry (PhRMA). PhRMA had a stake in the success of the health care overhaul proposed by President Obama. They spent over $28 million lobbying for the Patient Protection and Affordable Care Act (Obama care). In closed-door meetings in 2009, White House Chief of Staff Rahm Emanuel requested a television ad campaign to support Obama care which would run prior to the vote by Congress. The money for the ads was donated by PhRMA and funneled through political action committees set up by Jim Messina, the Deputy Chief of Staff (Blaine). In 2012, the FDA introduced the Food and Drug Administration Safety and Innovation Act which holds foreign manufacturers of pharmaceuticals to U.S. standards. Because of the higher standards, it limits the amount of drugs shipped from foreign countries and limits counterfeit drugs. The law appears to protect the public from harmful drugs, but it also limits the competition from foreign competition. The Act was supported by PhRMA, Senator Mike Enzi (R, Wyoming), and Congressman Henry Waxman (D, California) who worked diligently to move the bill quickly through the Senate and House. The Act was signed into law on July …show more content…

Two of these laws are the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act. Both of these acts allow the FDA to waive research for certain drugs that are already being used in adults such as some cancer drugs. In 2010, PhRMA spent $22 million on its lobbying efforts on health care issues. As a result of the work of over 50 lobbyists, laws were passed that were beneficial to its pharmaceutical clients. In exchange for their support of Obama care, it is believed that PhRMA will receive preference on future policies that will be worth billions to the industry (Blaine). Also, laws such as the Food and Drug Administration Safety and Innovation Act limits foreign competition and counterfeit drugs which will increase the profits of PhRMA's

Open Document